No Data
US Stock MarketDetailed Quotes
AGRX Agile Therapeutics
Watchlist
2.300
+0.100+4.55% Close 12/06 16:00 ET
2.3000.0000.00%
Post 16:39 ET
2.600High2.220Low60.41KVolume
2.590Open2.200Pre Close144.38KTurnover2.41%Turnover Ratio0.31P/E (TTM)5.78MMarket Cap16.00052wk HighLossP/E (Static)2.51MShares1.65052wk Low-0.47P/B5.77MFloat Cap26380.000Historical High--Dividend TTM2.51MShs Float1.650Historical Low--Div YieldTTM17.27%Amplitude2.389Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
About Agile Therapeutics Company
Agile Therapeutics, Inc. is a healthcare company, which engages in the development and commercialization of transdermal patches. Its lead product candidate, Twirla, also known as AG200-15, is an investigational low-dose, non-daily prescription contraceptive. The company was founded by Chien Te Yen on December 22, 1997 and is headquartered in Princeton, NJ.
Revenue Breakdown
Business
Currency:USD
2022/12/31
Stock NameRevenueRatio
Single segment10.88M100.00%
News
Agile Therapeutics Received A Letter Notifying The Company That It Had Been Granted Until Feb. 16, 2024, To Regain Compliance With The Minimum Stockholders' Equity Requirement For Continued Listing On The Nasdaq Capital Market
Agile Therapeutics Received A Letter Notifying The Company That It Had Been Granted Until Feb. 16, 2024, To Regain Compliance With The Minimum Stockholders' Equity Requirement For Continued Listing On
Agile Therapeutics Reports Q3 Results
Agile Therapeutics Posts Growth In Third Quarter Results, Reiterates Confidence In Target of $25M Net Revenue, Positive Cash Flow In 2024
PRINCETON, NJ / ACCESSWIRE / November 22, 2023 / Agile Therapeutics, Inc. (NASDAQ:AGRX), the commercial-stage women's healthcare company, posted a 122% increase in third-quarter revenue year-over-year
Comments
$Agile Therapeutics(AGRX.US$ Agile Therapeutics Partners With Telehealth Platforms To Expand Access To Weekly Birth Control Patch To Millions Of Women
1
Just now post the wrong ticker , ARGX is the correct with good news
$argenx SE(ARGX.US$argenx Reports Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy
$Agile Therapeutics(AGRX.US$
$Agile Therapeutics(AGRX.US$
1
Read more
Paper Trade
Start
Symbol
Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
Den the Dragon :
Mcsnacks H Tupack : They will wait until closing time to move it. If they are moving it.
RiveraOP Mcsnacks H Tupack: I’m holding abs loading